Establishes prescription drug pricing disclosure requirements and measures to reduce prescription drug costs.
Impact
The bill mandates that pharmacy benefits managers (PBMs) disclose crucial pricing information related to prescription drugs and require them to establish channels for consumer inquiries. It also obliges manufacturers and wholesale distributors to avoid excessive price increases—termed price gouging—without sufficient justification. If the price of an essential drug increases significantly, the Attorney General can investigate and require detailed reports from manufacturers concerning cost structures and justifications for price changes.
Summary
Senate Bill S323 aims to establish prescription drug pricing disclosure requirements and implement measures to reduce the costs of prescription drugs and biological products for consumers in New Jersey. The bill is designed to provide more transparency around drug pricing, specifically targeting essential off-patent and generic drugs. It defines 'essential off-patent or generic drug or biological product' based on availability, manufacturing restrictions, and public health designations, ensuring that price hikes on vital medications are scrutinized and regulated appropriately.
Contention
Notably, the bill has aimed to address the rising costs of prescription drugs which often impose a heavy burden on consumers, particularly in low-competition markets. Critics of the pharmaceutical industry emphasize the necessity of regulatory oversight to prevent exploitative practices, whereas some stakeholders within the industry express concerns about how these regulations could impact market dynamics and innovation. The establishment of a commission tasked with monitoring drug prices and potentially capping them introduces an additional layer of state intervention in pharmaceutical pricing, prompting debate over governmental versus market regulation.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.
An act to amend Section 4073.5 of the Business and Professions Code, to amend Section 1367.22 of the Health and Safety Code, and to add Section 10123.190 to the Insurance Code, relating to prescription drugs.